IDH2 and cholangiocarcinoma: The importance of the mutation is confirmed by the activity of IDH-inhibitors: inhibiting the mutant activity of either IDH1 or IDH2 shows anti-tumour activity in relapsed/refractory IDH1/2 mutated acute myeloid leukemia [14, 45] and cholangiocarcinoma patients [1].